Notably, three predominant biomarkers—estrogen receptor (ER), progesterone receptor (PR), and HER2—have become essential in clinical practice for identifying intrinsic breast cancer subtypes and guiding treatment decisions. This evidence concerns the gene ERBB2 and breast carcinoma.